新闻
Freshfields advises Evotec on divestment of Evotec DS Germany
Global law firm Freshfields is advising publicly listed Evotec SE on the divestment of Evotec DS Germany GmbH to Monacum Partners GmbH.
Evotec DS Germany is an EU GMP certified contract developer and manufacturer (CDMO) of active pharmaceutical ingredients with a drug substance manufacturing facility in Halle (Westphalia). Evotec SE is a life science company researching, developing and manufacturing highly effective therapeutics and is listed on the TecDAX and SDAX as well as on NASDAQ.
Freshfields advises Evotec SE on the corporate and tax structuring of the transaction, in particular the negotiation of the share purchase agreement, and provides advice on other relevant transaction aspects, inter alia IP and labour law.
Freshfields regularly advises Evotec with teams led by partner Christoph H. Seibt on corporate and capital markets law as well as on M&A and capital market transactions, including, on the Nasdaq IPO/Dual Listing at the end of 2021 or the acquisition of Italian biotech business Rigenerand in 2022.
The cross-practice Freshfields team is led by Partner Christoph H. Seibt and Principal Associate Maximilian Stöwahse (both Corporate/M&A, Hamburg) and includes inter alia:
- Partners: Alexander Schwahn (Tax, Hamburg), Katrin Gaßner (Antitrust, Düsseldorf) and Jan-Philip Wilde (Corporate/M&A, Hamburg)
- Counsel: Philipp Lehmann (Corporate/M&A, Hamburg)
- Principal Associates: Michael Bakowitz (Antitrust, Düsseldorf), Aljosha Barath (Corporate/M&A, Hamburg), Tobias Franz (Tax, Hamburg) and Björn Junior (Tax, Düsseldorf)
- Associates: Christoph Beckmann, Alexandra Harf (both Corporate/M&A, Hamburg), Severin Pretzel (Employment Law, Hamburg), Felix Schüßler, Vinia Stach and Sean Tries (all Corporate/M&A, Hamburg)
Evotec SE is advised inhouse by General Counsel Christian Dargel and SVP, Head of Global Business Development, Cell Therapy Bernd Mühlenweg.
